Adlai Nortye Ltd. American Depositary Shares – NASDAQ:ANL

Add to watchlist

$1.71

-0.69

-28.75%

Market closed

Open in about 8 hours

-26.15%

month

-26.15%

quarter

-73.45%

year

Market Cap	200.54M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-2.1

Revenue	N/A
EBITDA	-111.91M
Income	-104.87M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Adlai Nortye Ltd. American Depositary Shares (NASDAQ:ANL): Profit margin
Mar 2023	0	-15.02M
Jun 2023	0	-63.39M
Sep 2023	2.5M	-13.22M	-529.06%
Dec 2023	2.5M	-13.22M	-529.06%

Adlai Nortye Ltd. American Depositary Shares Financials Estimate

Q Y

Adlai Nortye Ltd. American Depositary Shares (NASDAQ:ANL): Analyst Estimates
2025	2.81M	-164.26M	-5845.67%
2026	335.4M	78.44M	23.39%
2027	926.7M	569.94M	61.5%
2028	1.28B	868.57M	67.36%

Analysts Price target
Financials & Ratios estimates

Adlai Nortye Ltd. American Depositary Shares (NASDAQ:ANL): Debt to assets
Mar 2023	67537000	322.44M	477.43%
Jun 2023	66496000	384.03M	577.52%
Sep 2023	130189000	50.78M	39.01%
Dec 2023	130189000	50.78M	39.01%

Adlai Nortye Ltd. American Depositary Shares (NASDAQ:ANL): Cash Flow
Mar 2023	-10.00M	21.32M	5.49M
Jun 2023	-8.31M	39K	9.46M
Sep 2023	-19.16M	-16.16M	50.63M
Dec 2023	-19.16M	-16.16M	50.63M

Adlai Nortye Ltd. American Depositary Shares alternative data

Adlai Nortye Ltd. American Depositary Shares
Employees

Adlai Nortye Ltd. American Depositary Shares (NASDAQ:ANL): Employee count
Oct 2023	130
Nov 2023	130
Dec 2023	130
Jan 2024	130
Feb 2024	130
Mar 2024	130
Apr 2024	130
May 2024	127
Jun 2024	127
Jul 2024	127

Adlai Nortye Ltd. American Depositary Shares
Latest News

Monday, 9 September 2024
10:35	Adlai Nortye Ltd. Sponsored ADR (ANL) Loses -33.06% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner	zacks.com
Thursday, 23 May 2024
21:03	Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024	globenewswire.com
Wednesday, 22 May 2024
08:00	Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy	globenewswire.com
Wednesday, 15 May 2024
10:40	Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year?	Zacks Investment Research
Thursday, 25 April 2024
10:46	Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?	Zacks Investment Research
Friday, 13 October 2023
08:00	Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles	Seeking Alpha
Saturday, 30 September 2023
03:30	U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline	Seeking Alpha

Ideas & Opinions

Seeking Alpha 3 Jan 2024

IPOs In 2023 Disappoint But 2024 Looks Brighter
Seeking Alpha 13 Oct 2023

Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles
Seeking Alpha 1 Oct 2023

Week In Review: Adlai Nortye Stages $97.5 Million U.S. IPO On NASDAQ
Seeking Alpha 30 Sep 2023

U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline

Frequently Asked Questions (FAQ)

What's the price of Adlai Nortye Ltd. American Depositary Shares stock today?

One share of Adlai Nortye Ltd. American Depositary Shares stock can currently be purchased for approximately $1.71.
When is Adlai Nortye Ltd. American Depositary Shares's next earnings date?

Unfortunately, Adlai Nortye Ltd. American Depositary Shares's (ANL) next earnings date is currently unknown.
Does Adlai Nortye Ltd. American Depositary Shares pay dividends?

No, Adlai Nortye Ltd. American Depositary Shares does not pay dividends.
How much money does Adlai Nortye Ltd. American Depositary Shares make?

Adlai Nortye Ltd. American Depositary Shares has a market capitalization of 200.54M.
What is Adlai Nortye Ltd. American Depositary Shares's stock symbol?

Adlai Nortye Ltd. American Depositary Shares is traded on the NASDAQ under the ticker symbol "ANL".
What is Adlai Nortye Ltd. American Depositary Shares's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Adlai Nortye Ltd. American Depositary Shares?

Shares of Adlai Nortye Ltd. American Depositary Shares can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Adlai Nortye Ltd. American Depositary Shares have?

As Jul 2024, Adlai Nortye Ltd. American Depositary Shares employs 127 workers, which is 2% less then previous quarter.
When Adlai Nortye Ltd. American Depositary Shares went public?

Adlai Nortye Ltd. American Depositary Shares is publicly traded company for just a year since IPO on 23 Sep 2023.
What is Adlai Nortye Ltd. American Depositary Shares's official website?

The official website for Adlai Nortye Ltd. American Depositary Shares is adlainortye.com.
How can i contact Adlai Nortye Ltd. American Depositary Shares?

Adlai Nortye Ltd. American Depositary Shares can be reached via phone at +84 82307430.

Adlai Nortye Ltd. American Depositary Shares

adlainortye.com

Exchange:

NASDAQ

Full time employees:

127

Industry:

Biotechnology

Sector:

Healthcare

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.

+84 82307430

Ugland House
Grand Cayman, KY1-1104

CIK: 0001944552
ISIN: US00704R1095
: